What is Monopar Therapeutics's operating lease liabilities?

Monopar Therapeutics (MNPR) reported operating lease liabilities of $131.57K in Q1 2026.

What does operating lease liabilities mean?

Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Monopar Therapeutics MNPR Operating Lease Liabilities

Operating Lease Liabilities at other companies

Prime MedicinePRME

$105.97M-7.3%

Wave Life SciencesWVE

$7.39M-53.0%

Perspective TherapeuticsCATX

$1.55M+32.2%

Amylyx Pharmaceuticals, Inc.AMLX

$4.48M+1,269%

ArriVent BioPharma, Inc.AVBP

$320K—

Lantheus HoldingsLNTH

$55.35M+16.4%

Other financials

Income statement

See full

Revenue-—

Operating income-$5.2M-62.2%

Net income-$3.9M-48.3%

EPS (diluted)-$0.19—

Balance sheet

See full

Cash & equivalents$52.5M+32.3%

Total debt$230.4K+2,692%

Total equity$135.4M+153%

Total assets$138.0M+150%

Cash flow

See full

Operating cash flow-$3.5M+38.7%

Valuation

See full

Market cap$587.04M+192%

Enterprise value$534.72M+232%

Returns & leverage

See full

Return on equity-15.9%-6.6pp

Debt / equity0×0.0×

Current ratio56×—

Where this comes from

Reported directly by Monopar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monopar Therapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monopar Therapeutics's operating lease liabilities?: Monopar Therapeutics (MNPR) reported operating lease liabilities of $131.57K in Q1 2026.
What does operating lease liabilities mean?: Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.